论文部分内容阅读
目的 探讨脂蛋白 (a) [Lipoprotein ,LP(a) ]在脑卒中发生、发展中的作用。 方法 用免疫透射比浊法测定 95例不同类型脑卒中患者与 35例对照组的血清LP(a) ,并与其他血脂指标、病程、病情作相关分析。结果 脑梗塞组血清LP(a)高于对照组 (P <0 0 1 ) ;皮层动脉梗塞组血清LP(a)高于穿通动脉梗塞组 (P <0 0 5) ;脑出血组血清LP(a)与对照组间无显著差异 (P >0 0 5) ;LP(a)与其他血脂指标及病程、病情间均无显著相关。结论 LP(a)可作为缺血性卒中的预报及不同动脉硬化病因的鉴别指标 ,但不能作为观察病情轻重及病情演变的指标
Objective To investigate the role of lipoprotein (a) [Lipoprotein, LP (a)] in the occurrence and development of stroke. Methods Serum LP (a) was measured by immunoturbidimetry in 95 patients with different types of stroke and 35 control subjects. The serum LP (a) levels were correlated with other blood lipid parameters, duration of disease and disease. Results Serum LP (a) in cerebral infarction group was significantly higher than that in control group (P <0.01). Serum LP (a) in cerebral infarction group was higher than that in perforating artery infarction group (P <0.05) There was no significant difference between the two groups (P> 0.05). There was no significant correlation between LP (a) and other blood lipids, duration of disease and illness. Conclusion LP (a) can be used as a predictor of ischemic stroke and differential diagnosis of atherosclerosis, but it can not be used as an index to observe the severity of disease and the evolution of disease